Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,714.00
(
-1.73%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
106.58
(
5.89%
)
Bitcoin
71,073.25
(
-3.88%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: sodrock post# 116640

Friday, 03/18/2011 3:42:45 PM

Friday, March 18, 2011 3:42:45 PM

Post# of 257257

I am confident that the FDA is using MNTA version of enoxaparin as the bar that needs to be met.

This is consistent with the political impetus from Congress to err on the side of caution in the wake of the Vioxx, Avandia, and contaminated-heparin incidents. Please see #msg-56450420 for related musings.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now